Is Medtronic (MDT) a risky stock?
As of July 21, 2026, Clavix grades Medtronic (MDT) B for risk, a composite score of 72 out of 100 on an A+ to F scale, which puts MDT in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind MDT's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how MDT scores on each, as of July 21, 2026.
What's moving MDT's risk right now
Company-specific signals Clavix flags behind MDT's current grade, drawn from recent news and filings as of July 21, 2026.
The outcome of this bellwether trial could set a precedent for thousands of similar lawsuits against MDT's hernia mesh products, potentially creating significant financial liabili…
The deal reinforces Medtronic's growth pipeline in a higher-margin, high-demand therapeutic area, potentially driving incremental revenue from pain management solutions while mode…
The new product strengthens MDT's position in the growing CGM market by addressing battery life, a critical pain point in wearable medical devices, and could drive incremental rev…
What a B grade means
On the Clavix A+ to F scale, MDT's composite of 72 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell MDT or any security. Grades are risk indicators, not predictions of return. Data may be delayed.